The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas

M Victoria Recouvreux1,2, M Andrea Camilletti1, Daniel B Rifkin3 and Graciela Díaz-Torga1

1Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Vuelta de Obligado 2490, 1428 Buenos Aires, Argentina
2Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
3Department of Cell Biology, New York University Medical Center, 550 First Avenue, New York, New York 10016, USA

Abstract

Prolactinomas are the most frequently observed pituitary adenomas and most of them respond well to conventional treatment with dopamine agonists (DAs). However, a subset of prolactinomas fails to respond to such therapies and is considered as DA-resistant prolactinomas (DARPs). New therapeutic approaches are necessary for these tumors. Transforming growth factor β1 (TGFβ1) is a known inhibitor of lactotroph cell proliferation and prolactin secretion, and it partly mediates dopamine inhibitory action. TGFβ1 is secreted to the extracellular matrix as an inactive latent complex, and its bioavailability is tightly regulated by different components of the TGFβ1 system including latent binding proteins, local activators (thrombospondin-1, matrix metalloproteases, integrins, among others), and TGFβ receptors. Pituitary TGFβ1 activity and the expression of different components of the TGFβ1 system are regulated by dopamine and estradiol. Prolactinomas (animal models and humans) present reduced TGFβ1 activity as well as reduced expression of several components of the TGFβ1 system. Therefore, restoration of TGFβ1 inhibitory activity represents a novel therapeutic approach to bypass dopamine action in DARPs. The aim of this review is to summarize the large literature supporting TGFβ1 important role as a local modulator of pituitary lactotroph function and to provide recent evidence of the restoration of TGFβ1 activity as an effective treatment in experimental prolactinomas.

Key Words
- resistant prolactinomas
- dopamine
- estradiol
- TGFβ1

Pituitary tumors

Pituitary tumors are commonly benign, slow growing adenomas, and account for 10–15% of all intracranial neoplasms (Farrell 2006, Melmed 2015). The prevalence of these tumors is relatively high in the general population, with ~77 cases per 100 000 (Daly et al. 2009, Fernandez et al. 2010), and studies of autopsy specimens identified up to a 20% prevalence of clinically occult pituitary adenomas (Ezzat et al. 2004). Despite their benign features, pituitary tumors can cause considerably morbidity due to both hypersecretion of pituitary trophic hormones and excessive tumor growth that can affect surrounding tissue. Common symptoms of a pituitary tumor compressive ‘mass effect’ include visual impairment, headaches, neurological disorders, and hypopituitarism caused by disruption of the hypothalamic–pituitary axis (Arafah & Nasrallah 2001, Melmed 2011). Based on their size, pituitary adenomas are classified as...
microadenomas (<10 mm), macroadenomas (>10 mm), or giant adenomas (>40 mm).

Pituitary tumors usually present with monoclonal growth and can also be classified according to their cell-type origin and hormone secretion. Thus, somatotrophinomas secrete growth hormone, prolactinomas secrete prolactin (PRL), thyrotrophinomas secrete thyroid-stimulating hormone, and corticotrophinomas secrete adrenocorticotropic hormone. In contrast, the non-functioning pituitary adenomas (NFPAs) do not produce any hormone.

Prolactinomas

Among functioning pituitary tumors, prolactinomas are the most frequently observed in the clinic (40%) (Ciccarelli et al. 2005). Excessive PRL secretion by these tumors leads to hyperprolactinemia, which primarily affects gonadal/reproductive function, causing hypogonadism, galactorrhea, decreased libido, and infertility both in men and women. Large macroprolactinomas can also cause neurological symptoms due to compression of adjacent tissues.

Prolactinomas are usually benign, and although some tumors show invasion into the parasellar compartment and/or sphenoid sinuses, malignant transformation and metastatic spread are extremely rare. Macroprolactinomas tend to be more aggressive and resistant to therapies than microprolactinomas (Wong et al. 2015a).

Differences in prolactinoma incidence, tumor size, and behavior have been described among genders. The prevalence of prolactinomas is higher in women during the fertile period (20–50 years), while the frequency is similar between sexes after the fifth decade of life (Colao et al. 2003, Gillam et al. 2006). Also, women usually present with microprolactinomas whereas men more often present with macroprolactinomas (Delgrange et al. 1997, Nishioka et al. 2003). These differences have been associated to the earlier diagnosis in woman due to the readily detection of symptoms caused by high prolactin (amenorrhea/galactorrhea) (Delgrange et al. 1997, Colao et al. 2003, Nishioka et al. 2003, Gillam et al. 2006). However, delayed diagnosis in men may not be the only explanation for the differences in tumor size, since young men also present with macroprolactinomas, and prolactinomas in men tend to be more aggressive, with higher proliferative indexes and lower rates of surgical cure, suggesting a sex-specific behavior for these tumors (Delgrange et al. 1997, Gillam & Molitch 2015).

Prolactinoma treatment

The major goals of treatment in patients with prolactinomas are to normalize serum PRL levels, to restore gonadal function, to reduce tumor size, and to preserve or improve residual pituitary function. Prolactin secretion in the normal pituitary is tonically inhibited by hypothalamic dopamine through dopamine D2 receptors (Drd2) expressed on lactotroph cell membranes (Ben Jonathan & Hnasko 2001). The majority of prolactinomas retain an intact response to dopamine inhibition; therefore, medical treatment with dopamine agonists (DAs), such as cabergoline and bromocriptine, represents the first-line therapy for this tumors, including microprolactinomas, macroprolactinomas, and giant prolactinomas (Wong et al. 2015b). DAs are highly effective in achieving therapeutic aims with a favorable benefit/risk balance compared with surgical treatment.

DA-resistant prolactinomas

Despite the universal use of DAs and their high efficiency in reducing PRL levels and decreasing tumor size, there is a subset of prolactinomas (10–15%) that do not respond appropriately to the treatment, even at high doses of DA (Vroonen et al. 2012). These tumors represent a major challenge for clinical management. DA-resistant prolactinomas (DARPs) are more prevalent in men than women, occur most frequently as macroprolactinomas, and tend to be invasive, exhibiting extension to the cavernous sinuses.

The molecular mechanisms underlying the escape from dopaminergic regulation in DARPs are not fully elucidated. The main candidate thought to be responsible for resistance is the Drd2 itself. However, to date, no point mutation in the Drd2 gene has been identified in DARPs (Friedman et al. 1994, Molitch 2003, 2014, Gillam et al. 2006, Vroonen et al. 2012). Nevertheless, several mechanisms that lead to reduced Drd2 sensitivity were described in resistant prolactinomas, including evidence of decreased Drd2 mRNA expression, and differential expression of short and long Drd2 isoforms (Caccavelli et al. 1994, Vasiliev et al. 2011, Shimazu et al. 2012) reduced Drd2 density and dopamine binding sites in plasma membranes of DARPs cells (Pellegrini et al. 1989). Alterations in dopamine signaling, such as decreased expression of the inhibitory alpha G protein subunit (G suic ), have also been described (Caccavelli et al. 1996), as well as decreased expression of the nerve growth factor receptor, which indirectly modulates Drd2 expression (Passos et al. 2009). Histological studies on DARPs also revealed increased...
angiogenesis, cellular atypia (multinucleated cells, irregular nuclei), and increased proliferation index measured by Ki67 staining, indicating an overall increase invasiveness (reviewed in Gurlek et al. (2007)).

**Alternative treatments for DARPs**

At present, there is no alternative medical treatment for DARPs, and transsphenoidal surgery is indicated if the tumor is still resectable (Primeau et al. 2012, Smith et al. 2015). However, some aggressive prolactinomas recur post-operatively and show progressive growth, in which case radiotherapy is the next therapeutic option, but with limited efficiency (Molitch 2014).

The chemotherapy agent temozolomide (TMZ) has been recently used as a last resort therapy and showed a moderately successful response in large aggressive DARPs (McCormack et al. 2011, Whitelaw et al. 2012, Liu et al. 2015). However, the efficacy of TMZ therapy in aggressive pituitary adenomas remains controversial (Bruno et al. 2015), and clinical trials are now necessary to establish the indications, doses, and duration of TMZ administration to more accurately determine the efficacy of this agent.

New therapeutic approaches are necessary for those prolactinomas that are resistant to conventional treatments. Few reports of experimental treatments can be found in the literature and show variable effectiveness in pre-clinical and *in vitro* models. For instance, treatment with somatostatin receptor (SSTR) analogs failed to inhibit prolactin secretion by cultured cells derived from DARPs (Fusco et al. 2008) despite the expression of all subtypes of SSTR in human prolactinomas (Jaquet et al. 1999).

Based on the counteracting effects of estradiol on dopamine action in lactotrophs, targeting of the estrogen receptor with tamoxifen was evaluated in the pre-cabergoline era in patients with bromocriptine-resistant prolactinomas, but only a reduced reduction in PRL levels were observed (Volker et al. 1982). A novel anti-estrogen agent, fulvestrant, also reduced PRL secretion in pituitary cell lines and decreased tumor growth and serum PRL in estrogen-induced prolactinomas in rats (Cao et al. 2014).

**In the search for new therapeutic targets for DARPs**

Studies in animal models of prolactinomas with altered sensitivity to DA, such as the estrogen-induced prolactinomas in rats and the Drd2 knockout mice (Drd2<sup>−/−</sup>), have been very helpful to identify molecular pathways altered in these tumors and to test potential future therapies. Many of these studies suggest that the deregulation of local growth factors and extracellular matrix (ECM) remodeling participate in the pathogenesis of prolactinomas by promoting cell proliferation, angiogenesis, and invasiveness (Paez-Pereda et al. 2005, Cristina et al. 2005, 2007, Recouvreux et al. 2013).

Transforming growth factor β1 (TGFβ1), a well-known inhibitor in lactotroph physiology, has been recently identified as a novel target for the development of new therapies in resistant prolactinomas.

**The complexity of the TGFβ system and biology**

TGFβs are multifunctional cytokines known to play crucial regulatory roles in cellular proliferation and differentiation, angiogenesis, ECM modification, and immunomodulation (Yoshinaga et al. 2008), and have powerful effects on embryogenesis, development, and tissue homeostasis (Heldin et al. 2009, Galvin-Burgess et al. 2013, Itoh et al. 2014). The TGFβ family comprises more than 30 highly pleiotropic molecules including activins, inhibins, nodal, bone morphogenetic proteins (BMPs), the anti-Müllerian hormone, and several growth and differentiation factors among others (Derynck & Akhurst 2007). Three isoforms of TGFβ have been identified (TGFβ1, 2, and 3).

The importance of TGFβ1 is clearly demonstrated by the fact that TGFβ1 null mutation causes excessive inflammatory response and early death (Kulkarni et al. 1993). On the contrary, an excess of TGFβ1 activity is associated to connective tissue diseases, fibrosis and inflammation, cirrhosis, arthritis and sclerosis, cardiovascular diseases, and cancer, making TGFβ an interesting target for therapeutic research (Pohlers et al. 2009, Akhurst & Hata 2012, Doyle et al. 2012).

Nearly all cell types are sensitive to TGFβ1, but TGFβ action is highly dependent on cell type, developmental stage, physiological–pathological conditions, interaction with components of the ECM and, once bond to its receptor, interaction with other signaling pathways.

The potent biological activity of TGFβ1 is tightly regulated at different levels, including its synthesis, secretion, storage, and activation. The three TGFβ isoforms are synthesized as homodimeric precursor molecules that contain a pro-peptide sequence, so-called latency-associated peptide (LAP), and the functional mature TGFβ sequence (Fig. 1, 1). After proteolytic processing by furin within the trans-Golgi, LAP remains associated with the mature TGFβ by non-covalent interactions in a small latent
complex (Fig. 1, 2). While in the endoplasmic reticulum, LAP is linked, by disulfide bonds, with a latent TGF-β-binding protein (LTBP) (Fig. 1, 3). LTBP1s belong to a family of large secretory ECM glycoproteins. Although LTBP1s are not required for maintenance of TGF-β latency, they facilitate the secretion, storage, and activation of the TGF-β–LAP complex (Rifkin 2005).

TGF-β is secreted as part of this large latent TGF-β complex (LLC; Fig. 1, 3) and is incorporated as component of the ECM, which acts as a reservoir of the cytokine (4). TGF-β must undergo a highly regulated activation process by which mature cytokine is released (5) to enable binding to its receptor complex (TβRI and TβRII) (6) and signal through Smad2/Smad3 pathway (7). Known TGF-β activators are listed in the upper left.

Once TGF-β1 is released from the ECM, the active cytokine binds to its transmembrane receptor, the type II TGF-β receptor (TβRII), a constitutively active kinase that recruits and phosphorylates type I TGF-β receptor (TβRI) forming a heterotetrameric complex of serine/threonine kinase receptors containing two type I and two type II subunits (Fig. 1, 6). Next, TβRI phosphorylates the downstream receptor-associated Smads (R-Smads: Smad2/Smad3), which form a heteromeric complex with Smad4, and translocate to the nucleus to regulate the transcription of target genes (Fig. 1, 7). Additionally, an inhibitory Smad, Smad7, competes with the Smad2/3 for binding to the activated TβRI, thereby exerting a negative effect on TGF-β/Smad signaling (Shi & Massague 2003, Han et al. 2015).
This pathway is known as ‘the canonical’ TGFβ signaling pathway. However, TGFβ can also signal through Smad-independent pathways including the mitogen-activated protein kinase (ERK1/2, JNK, p38), small GTP-binding proteins (Ras, RhoA, Rac1, CDC42, mTOR), the NF-κB pathway and Wnt/β-catenin pathway, the AKT/PKB pathway, and phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) (Attisano & Wrana 2002, Moustakas & Heldin 2005).

As a multifunctional cytokine with powerful effects on cell proliferation, cellular migration, and inflammation, TGFβ signaling has been targeted for drug development, and numerous strategies have proceeded through preclinical to clinical trials (reviewed in Akhurst & Hata (2012)).

### TGFβ1 in the pituitary: a brief history

The earliest publications on TGFβ1 action in the pituitary date from the late 1980s and early 1990s (Ying et al. 1986, Mueller & Kudlow 1991). Sarkar et al. (1992) were the first to demonstrate local TGFβ1 mRNA and protein expression in the pituitary gland, and the inhibitory action of TGFβ1 on prolactin secretion and lactotrophic growth in 1992.

Although these first evidences were found in animal models (rat), TGFβ1 and TβRII expression were promptly found to be expressed in human pituitaries (Halper et al. 1992, Fujiwara et al. 1995), as well as in human pituitary adenomas (Fujiwara et al. 1995, Jin et al. 1997).

The main physiological modulators of lactotroph function are dopamine and estradiol, which exert inhibitory and stimulatory actions respectively (Ben Jonathan & Hnasko 2001). The pro-mitotic effect of estradiol (pharmacological doses) and its role in prolactinoma induction is very well described in the literature (Heaney et al. 2002). However, estradiol also participate in the lactotroph cell turnover in normal pituitary glands, sensitizing lactotroph cells to apoptotic stimuli. Therefore, the effect of estradiol on lactotroph function depends on the dose and normal/tumoral condition of the cells (Pisera et al. 2004, Zaldívar et al. 2009, Jaita et al. 2015). Interestingly, dopamine and estradiol also regulate the expression of both TGFβ1 and its receptor, but in opposite ways. Thus, while estrogen stimulation increases serum PRL levels and lactotroph proliferation, it decreases the expression of TGFβ1 in the anterior pituitary. On the contrary, dopamine, acting through the Drd2, up-regulates TGFβ1 expression and secretion in vivo and in vitro, with a concomitant reduction in the proliferation rate of lactotrophs. Moreover, it has been proposed that TGFβ1 partially mediates the inhibitory effect of dopamine on lactotroph proliferation (Sarkar et al. 2005). Our group has recently described that the amount of pituitary active TGFβ1 is also locally regulated by dopamine and estradiol treatment in mice; moreover, we found an inverse correlation between active TGFβ1 levels and serum PRL (Recouvreux et al. 2011). It is worth noting that <8% of total pituitary TGFβ1 was found in the active form, similar to what has been described in other tissues (Yoshinaga et al. 2008). This underscores the tightly regulation of the latent TGFβ1 activation process.

Other important factor regulating lactotroph homeostasis is PRL itself, acting through the PRL receptor (PRLR). It has been shown that endogenous PRL exerts paracrine/autocrine anti-proliferative and proapoptotic effects on lactotrophs; moreover, knockout mice lacking PRLR develop prolactinomas, further demonstrating the important role of PRL in the negative feedback on lactotroph function (Schuff et al. 2002, Ferraris et al. 2012, 2014).

Whether PRL can as well regulate TGFβ1 expression or function in the pituitary gland is an open question that has not yet been addressed.

### Alterations in the components of the TGFβ1 system during prolactinoma development

#### Evidences of TGFβ1 alterations in estradiol-induced prolactinomas in rats

The estrogen-treated rat is a well-known model for prolactinoma development with increased pituitary weight, hyperprolactinemia, lactotroph hyperplasia, and reduced dopaminergic action at the pituitary level (Heaney et al. 1999, 2002). Furthermore, estradiol treatment decreases pituitary TGFβ1 and TβRII mRNA and protein, together with an increase in PRL levels (Sarkar et al. 1992, Pastorcic et al. 1995, De et al. 1996) (Fig. 2). Therefore, the inhibition of TGFβ1 and TβRII might cooperate in the development of prolactinomas induced by estradiol (Hentges & Sarkar 2001). In agreement with this idea, pituitary tumorigenesis induced by estrogen treatment is greatly accelerated in TβRII heterozygous knockout mice (TβRII+/−) where the expression of TβRII is markedly reduced (Shida et al. 1998).

#### TGFβ1 alterations in the prolactinoma development in Drd2−/− mice

Another well-characterized model to study prolactinoma development are the transgenic knockout mice lacking functional Drd2 (Drd2−/−). This model represents an...
excellent model to mimick DA resistance. Because of the absence of inhibitory dopaminergic control, these mice display chronic hyperprolactinemia and lactotroph hyperplasia (Kelly et al. 1997, Diaz-Torga et al. 2002, Cristina et al. 2006), but the loss of dopamine inhibition has deeper effect on pituitary function in female than in male mice (Saiardi et al. 1997, Diaz-Torga et al. 2002). In females, the increase in serum prolactin levels is much more pronounced than in males, and females develop lactotroph hyperplasia from 6 months onwards, while age-matched Drd2-deficient males develop pituitary lactotroph adenomas at 17–20 months of age (Asa et al. 1999).

Interestingly, active and total TGFβ1 levels, as well as TβRII and LTBP1 expression, are reduced in Drd2−/− pituitaries compared to controls (WT), highlighting the stimulatory role of dopamine on pituitary TGFβ1 system (Recouvreux et al. 2011) (Fig. 2). On the other hand, the impact of the chronic loss of dopaminergic tone on the TGFβ1 system was also stronger in females, evidenced by the down-regulation of several putative TGFβ1 activators (MMP2, MMP9, MT1–MMP, TSP1, and kallikrein) as well as the decreased expression of TGFβ1 target genes observed only in females (Drd2−/− vs their WT counterpart). In this model, we found sex differences in the regulation of the TGFβ1 system: males express higher levels of several components of the TGFβ1 system, and it could be due to the lower serum estradiol levels present in males, as estradiol negatively controls most of the components of the system (Recouvreux et al. 2013). We suggest that stronger pituitary TGFβ1 system could protect males from excessive lactotroph proliferation and prolactinoma development. Then, sex differences found in the regulation of the TGFβ1 system could explain sex differences found in the incidence of prolactinoma development in this model.

**TGFβ1 alterations in human pituitary tumors**

In humans, the expression of several components of the TGFβ signaling pathway was recently compared in five normal human anterior pituitaries, 29 invasive NFPAs and 21 non-invasive NFPAs (Zhenye et al. 2014). This report demonstrated that TGFβ1 mRNA expression and p-Smad3 protein levels gradually decreased, while Smad7 mRNA levels gradually increased from normal anterior pituitaries to non-invasive NFPAs and invasive NFPAs. The authors concluded that the activity of TGFβ signaling would be limited during tumor development.

Recent work also described a significant down-regulation of the TGFβ1/Smad signaling cascade in 12 cases of DARPs compared to normal human anterior pituitaries. The authors showed that TGFβ1 mRNA levels,
Smad2 and Smad3 mRNA, and protein expression were significantly decreased in human prolactinomas (Li et al. 2015, Fig. 2).

Overall, decreased TGFβ1 activity and decreased expression of different components of the TGFβ1 system have been described in animal models of prolactinomas as well as in human prolactinomas. Taking into account that TGFβ1 inhibits lactotroph proliferation and PRL synthesis and secretion, we speculate that recovering local TGFβ1 activity could contribute to revert the adenoma development and to normalize hyperprolactinemia.

**Recovery of local TGFβ1 activity: successful treatment in an experimental model of prolactinoma**

TSP1 is one of the main physiologic latent TGFβ1 activators in vitro and in vivo (Schultz-Cherry et al. 1994). TSP1 is a large multifunctional matrix glycoprotein involved in cell growth, adhesion, and migration (Lawler 2002). TSP1 also functions as an endogenous anti-angiogenic factor, inhibiting the proliferation and migration of endothelial cells by interaction with its cell surface receptor CD36 and by antagonizing VEGF activity (Lawler & Lawler 2012).

Based on the CD36-binding peptide sequence from TSP1, small molecules were developed to mimic TSP1 anti-angiogenic properties (Haviv et al. 2005). Several of these new drugs were able to slow tumor growth in preclinical models (Anderson et al. 2007, Yang et al. 2007, Garside et al. 2010). Among them, ABT-510 and ABT-898 (Abbott Laboratories), two of such TSP1 analogs, were assayed in several solid tumors (Haviv et al. 2005). ABT-510 was evaluated in phase II clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, lymphoma, and renal cell carcinoma (Haviv et al. 2005, Ebbinghaus et al. 2007, Markovic et al. 2007, Yang et al. 2007, Gordon et al. 2008, Nabors et al. 2010). The second-generation TSP1 synthetic analogue, ABT-898, was found to have greater potency than ABT-510 and is expected to have greater efficacy than the other available TSP1 mimetic peptides (Garside et al. 2010, Campbell et al. 2011) due to its lower clearance rate.

Immunoreactive TSP1 is present in the anterior pituitary, particularly in endothelial cells (Burns & Sarkar 1993), and TSP1 levels and its anti-angiogenic effect are reduced in prolactinomas induced by estradiol in rats (Sarkar et al. 2007) and in the hyperplastic pituitaries of Drd2−/− mice (Recouvreux et al. 2013). TSP1 expression was also found down-regulated in invasive vs non-invasive prolactinomas in humans (Jiang et al. 2012).

Given that: i) TSP1 is an anti-angiogenic factor, ii) TSP1 expression is reduced during prolactinoma development, iii) TSP1 is a known TGFβ1 activator, iv) TGFβ1 activity is also reduced during the development of prolactinomas, and v) TGFβ1 is an inhibitory factor of lactotroph proliferation and synthesis, we speculated that treatments that improve pituitary TSP1 and/or TGFβ1 activities could reduce the progression of prolactinomas.

![Figure 3](http://joe.endocrinology-journals.org/C209/2016/SocietyforEndocrinology/DOI:10.1530/JOE-15-0451/PrintedinGreatBritain/DownloadedfromBioscientifica.comat12/18/201812:10:18PM) via free access

**Figure 3**

Recovery of TGFβ1 activity emerges as a novel therapeutic target for treatment of dopamine agonist resistant prolactinomas. Treatment with thrombospondin-1 analogs (ABT-510, ABT-898) recover pituitary TGFβ1 activity, reduce tumor size, tumor angiogenesis, and proliferation markers, as well as serum prolactin in estradiol-induced prolactinomas in female rats.
We first evaluated whether the TSP1 analogs were able to activate TGFβ1 in the pituitary. In fact, an in vivo short-term treatment (100 mg/kg ABT-510 i.p.; 30 min) enhanced the biological activity of pituitary TGFβ1, with a concomitant reduction in serum prolactin levels (Recouvreux et al. 2012). Notably, same effect was observed after short-term treatment with ABT-510 in female rats carrying prolactinoma induced by chronic estradiol treatment. We next evaluated whether an in vivo treatment for 2 weeks with the TSP1 analogs could counteract the development of estradiol-induced prolactinomas in rats. ABT-510 and ABT-898 treatment (100 mg/kg i.p., thrice a week for 2 weeks) significantly decreased pituitary tumor size and reduced tissue angiogenesis and pituitary proliferation markers, as well as serum prolactin levels, in female rats with prolactinomas induced by chronic treatment with estradiol (Recouvreux et al. 2012). Furthermore, ABT-510 and ABT-898 treatment markedly increased active TGFβ1 content, measured by ELISA within the tumors. The increase in cytokine activation was also reflected in the recovery of intrapituitary p-Smad2/3 expression (Fig. 3). Besides from the well-known anti-angiogenic effect of these TSP1 mimetic peptides, the improvement of the local TGFβ1 biological activity most likely contributed to the reduction in serum prolactin and in the inhibition of prolactinoma growth.

Overall conclusions and perspectives

Prolactinomas are the most frequent pituitary tumors in adults accounting for 60% of all functioning pituitary tumors (Ciccarelli et al. 2005). Even though prolactinomas are usually benign and in most cases respond well to treatment with dopaminergic agents, 15% of these tumors are resistant to classical therapy, become invasive and aggressive, and require extirpation. The mechanisms underlying the escape from dopaminergic regulation in DARPs are not fully understood, and the main candidate to be responsible for resistance is the Drd2 itself. Since TGFβ1 mediates, at least partially, the inhibitory action exerted by dopamine on lactotrophs, and reduced TGFβ1 activity is a common feature of prolactinoma development, treatments that improve pituitary TGFβ1 activity represent a rational approach to develop alternative therapies for DARPs. Supporting this, we provide evidence of the effectiveness of a treatment with the small TSP1 analog peptides ABT-510 and ABT-898 to restore TGFβ1 activity and to counteract prolactinoma development in rats.

Taken together the data summarized here, the recovery of TGFβ1 activity emerges as a novel therapeutic target for treatment of DARPs.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

Funding
This work was supported by the Agencia Nacional de Promoción Científica y Técnica, Buenos Aires, Argentina (grant PICT 2013–2016 N2136 to G D-T), and the National Institutes of Health (grant R01 CA034282–25 to D B R).

Acknowledgements
We thank the National Institute of Diabetes and Digestive and Kidney Diseases National Hormone and Pituitary Program and Dr A F Parlow for prolactin RIA kits.

References


Ben Jonathan N & Hnasko R 2001 Dopamine as a prolactin (PRL) inhibitor. Endocrine Reviews 22 724–763. (doi:10.1210/edrv.22.6.0451)


Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P & Enjalbert A 1996 Alteration of G alpha subunits mRNA levels in bromocriptine resistant...


Ying SY, Becker A, Baird A, Ling N, Ueno N, Esch F & Guillemin R 1986 Type β transforming growth factor (TGF-β) is a potent stimulator of the basal secretion of follicle stimulating hormone (FSH) in a pituitary monolayer system. *Biochemical and Biophysical Research Communications* **135** 950–956. (doi:10.1016/0006-291X(96)91020-X)


Received in final form 10 December 2015
Accepted 22 December 2015
Accepted Preprint published online 23 December 2015

M V RECOUVREUX and others

**TGFβ1 and resistant prolactinomas**

228:3

http://joe.endocrinology-journals.org

DOI: 10.1530/JOE-15-0451

© 2016 Society for Endocrinology

Printed in Great Britain

Published by Bioscientifica Ltd.